Loading...
Pharmaceutical Importer · Kazakhstan · Antifungals Focus · $1.9M Total Trade · DGFT Verified
LLP "dari-pharm (kazakhstan) is a pharmaceutical importer based in Kazakhstan with a total trade value of $1.9M across 5 products in 5 therapeutic categories. Based on 78 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments.
LLP "dari-pharm (kazakhstan) imports across 5 therapeutic categories, with Antifungals (48.7%), Antihistamines & Allergy (19.0%), Immunosuppressants (14.2%) representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.
Antifungals
1 products · 48.7% · $922.6K
Antihistamines & Allergy
1 products · 19.0% · $359.7K
Immunosuppressants
1 products · 14.2% · $269.0K
Advanced Antibiotics
1 products · 9.2% · $174.5K
Vitamins & Supplements
1 products · 8.8% · $167.5K
| # | Product | Category | Value | Ships | Share | Rk |
|---|---|---|---|---|---|---|
| 1 | Ketoconazole | Antifungals | $922.6K | 39 | 2.3% | 10 |
| 2 | Chlorpheniramine | Antihistamines & Allergy | $359.7K | 8 | 0.8% | 10 |
| 3 | Leflunomide | Immunosuppressants | $269.0K | 10 | 1.8% | 10 |
| 4 | Ornidazole | Advanced Antibiotics | $174.5K | 7 | 1.0% | 13 |
| 5 | Biotin | Vitamins & Supplements | $167.5K | 14 | 10.9% | 3 |
LLP "dari-pharm (kazakhstan) imports 5 pharmaceutical products across 5 categories into Kazakhstan totaling $1.9M.
Shipment-level records, supplier connections & pricing for LLP "dari-pharm (kazakhstan).
Request DemoCompany type, headquarters, distribution network, and industry role
LLP "Dari-Pharm (Kazakhstan)" is a pharmaceutical importer and distributor headquartered in Almaty, Kazakhstan. Established to meet the growing demand for quality pharmaceutical products, the company plays a pivotal role in the nation's healthcare supply chain by sourcing and distributing a diverse range of finished pharmaceutical formulations. These products encompass tablets, capsules, syrups, and injections, catering to various therapeutic needs.
The company's operations are characterized by a strong focus on importing finished pharmaceutical products, primarily from India. This strategic sourcing approach enables LLP "Dari-Pharm (Kazakhstan)" to offer a comprehensive portfolio of medications across multiple therapeutic categories, thereby enhancing the accessibility and affordability of essential medicines within Kazakhstan.
LLP "Dari-Pharm (Kazakhstan)" maintains a centralized distribution model with its primary warehouse located in Almaty. This strategic location facilitates efficient logistics and distribution throughout Kazakhstan, ensuring timely delivery of pharmaceutical products to various healthcare facilities, including hospitals, clinics, and pharmacies. The company's logistics capabilities are designed to support a wide geographic coverage, effectively serving both urban and rural regions across the country.
In Kazakhstan's pharmaceutical supply chain, LLP "Dari-Pharm (Kazakhstan)" functions as a key importer and distributor of finished pharmaceutical formulations. By sourcing a diverse range of medications from international suppliers, particularly from India, the company ensures a steady supply of essential drugs to meet the healthcare needs of the population. Its role is crucial in bridging the gap between global pharmaceutical manufacturers and the local market, thereby contributing to the overall health infrastructure of Kazakhstan.
Sourcing concentration, supply chain resilience, and strategic implications
LLP "Dari-Pharm (Kazakhstan)" exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. This concentrated sourcing strategy allows the company to leverage established relationships with Indian suppliers, ensuring consistent product quality and availability. However, such dependency on a single source country may pose risks related to supply chain disruptions, currency fluctuations, and geopolitical factors. The company's import data indicates a stable relationship with its Indian suppliers, as evidenced by the consistent volume of shipments over the years. Nonetheless, it is advisable for the company to explore diversification strategies to mitigate potential risks associated with this sourcing concentration.
The resilience of LLP "Dari-Pharm (Kazakhstan)"'s supply chain is closely tied to its reliance on Indian pharmaceutical manufacturers. While the company benefits from established partnerships and a consistent supply of products, this dependence also exposes it to risks such as supply chain disruptions, regulatory changes, and geopolitical tensions affecting trade routes. To enhance supply chain resilience, the company could consider diversifying its supplier base by engaging with manufacturers from other countries, thereby reducing the impact of potential disruptions from any single source.
Regulatory authority, GMP requirements, import licensing for Kazakhstan
In Kazakhstan, the regulation of pharmaceutical imports is overseen by the Ministry of Healthcare, which is responsible for ensuring the safety, efficacy, and quality of medical products entering the country. Key legislation governing pharmaceutical imports includes the Code of the Republic of Kazakhstan "On the Health of the People and the Healthcare System," which outlines the procedures for the circulation of medicines, including importation, registration, and distribution. The marketing authorization pathway for Indian generics involves obtaining registration from the Ministry of Healthcare, which requires submission of comprehensive documentation demonstrating the product's compliance with Kazakhstan's regulatory standards.
Import licensing requirements for pharmaceutical products in Kazakhstan stipulate that all imported medicines must be registered with the Ministry of Healthcare prior to entry into the market. This process involves providing detailed information about the product, including its composition, manufacturing process, and evidence of its safety and efficacy. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are typically recognized by Kazakhstan's regulatory authorities. Importers must ensure that their suppliers hold valid GMP certifications to facilitate the importation process. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Kazakhstan, ensuring compliance with local regulations and standards.
Product strategy, sourcing profile, and market positioning
LLP "Dari-Pharm (Kazakhstan)"'s focus on importing finished pharmaceutical formulations across therapeutic categories such as antifungals, antihistamines, and immunosuppressants aligns with the prevalent healthcare needs in Kazakhstan. The demand for these products is driven by factors such as the prevalence of fungal infections, allergic conditions, and autoimmune diseases within the population. By concentrating on these therapeutic areas, the company addresses critical health concerns, thereby contributing to the overall well-being of the community.
The company's sourcing strategy is centered on procuring generic drugs, primarily from India, which offers a cost-effective and reliable supply of pharmaceutical products. Formulation preferences are guided by market demand and therapeutic needs, ensuring that the imported products are relevant and beneficial to the local population. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for LLP "Dari-Pharm (Kazakhstan)" in fulfilling its procurement objectives.
Opportunity assessment, qualifications, and practical approach strategy
There is a realistic opportunity for new Indian suppliers to engage with LLP "Dari-Pharm (Kazakhstan)" by offering high-quality generic pharmaceutical products that meet Kazakhstan's regulatory standards. Gaps in the company's current sourcing may include specific therapeutic areas or product forms not currently covered. By identifying these gaps and providing suitable products, new suppliers can establish a mutually beneficial partnership with the company, thereby expanding their market presence in Kazakhstan.
Indian exporters seeking to supply LLP "Dari-Pharm (Kazakhstan)" and the broader Kazakhstan market must ensure that their products are registered with the Ministry of Healthcare of Kazakhstan. They must hold valid GMP certifications from recognized authorities such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with Kazakhstan's labeling requirements, including the use of Kazakh and Russian languages, and adherence to serialization mandates are essential. Ensuring these qualifications will facilitate smoother market entry and acceptance of products within Kazakhstan.
LLP "dari-pharm (kazakhstan) imports 5 pharmaceutical products across 5 categories. Top imports: Ketoconazole ($922.6K), Chlorpheniramine ($359.7K), Leflunomide ($269.0K), Ornidazole ($174.5K), Biotin ($167.5K).
LLP "dari-pharm (kazakhstan)'s total pharmaceutical import value from India is $1.9M, based on 78 verified shipments in Indian Customs (DGFT) data.
LLP "dari-pharm (kazakhstan) imports across 5 categories. The largest: Antifungals (48.7%), Antihistamines & Allergy (19.0%), Immunosuppressants (14.2%).
Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.
The concentrated sourcing pattern of LLP "Dari-Pharm (Kazakhstan)" positions it to benefit from strong supplier relationships and potentially favorable pricing from Indian manufacturers. However, this strategy also exposes the company to risks associated with over-reliance on a single supplier base. For Indian exporters, the company's established import channels present an opportunity to strengthen and expand their market presence in Kazakhstan. By ensuring consistent product quality and compliance with Kazakhstan's regulatory standards, Indian exporters can enhance their competitiveness and appeal to LLP "Dari-Pharm (Kazakhstan)" as a preferred supplier.
Pharmaceutical products imported into Kazakhstan are subject to batch testing to verify their quality, safety, and efficacy. Stability requirements are enforced to ensure that products maintain their intended quality throughout their shelf life under specified storage conditions. Labeling must be in the Kazakh and Russian languages, providing essential information such as dosage instructions, expiration dates, and storage conditions. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the market, thereby safeguarding public health.
Between 2024 and 2026, Kazakhstan has implemented several policy changes affecting pharmaceutical imports. These include updates to the registration procedures for foreign-manufactured drugs, stricter enforcement of GMP certification requirements, and the introduction of new labeling and serialization standards to improve product traceability and combat counterfeit medicines. Importers and exporters must stay informed about these regulatory changes to ensure compliance and maintain uninterrupted market access.
Based on its product mix, LLP "Dari-Pharm (Kazakhstan)" serves multiple segments of the Kazakhstan market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. By offering a diverse range of pharmaceutical products, the company ensures that various healthcare providers have access to essential medications, thereby supporting the country's healthcare infrastructure and meeting the needs of different patient populations.
To build a relationship with LLP "Dari-Pharm (Kazakhstan)," Indian exporters should initiate contact by providing detailed product information, including regulatory approvals and certifications. Participating in tenders and responding to requests for proposals can demonstrate commitment and capability. Developing a clear regulatory filing strategy, including understanding the registration process and timelines, is crucial. Setting realistic expectations regarding approval times and market entry will aid in establishing a successful partnership.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5 Products Tracked
5 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists